Lilly(US:LLY) GLP1减重宝典·2025-06-11 03:01Core Viewpoint - Eli Lilly's dual receptor agonist, Tirzepatide injection, has had its new indication application accepted by the National Medical Products Administration, with speculation that it targets obstructive sleep apnea (OSA), potentially making it the first drug in China specifically for OSA treatment [2]. Group 1: Drug Development and Approvals - Tirzepatide is a GLP-1 and GIP dual receptor agonist that regulates appetite, energy intake, and metabolic function [2]. - The drug was approved by the FDA in the U.S. in May 2022 for diabetes treatment under the brand name Mounjaro® [2]. - In November 2023, it received approval for weight loss and is expected to be approved for moderate to severe OSA treatment by December 2024, marketed as Zepbound® [2]. - In China, Tirzepatide's diabetes indication was approved on May 21, 2024, and the weight loss indication was approved on July 19, 2024, both under the brand name "穆峰达®" [4]. Group 2: Market Potential and Applications - Eli Lilly is expanding Tirzepatide's clinical applications beyond diabetes and weight loss to include cardiovascular diseases, chronic kidney disease, and non-alcoholic fatty liver disease (NASH), targeting a total of nine chronic disease areas [4]. - OSA is a common sleep-related breathing disorder that can lead to various cardiovascular and metabolic diseases, including hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation, and type 2 diabetes [2].